Experimental HIV vaccine passes first safety check in healthy volunteers
NCT ID NCT06033209
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 21 times
Summary
This early-stage trial tested a new HIV vaccine candidate in 57 healthy adults without HIV. The vaccine uses a protein designed to train the immune system to recognize HIV. The main goals were to check safety and see if the vaccine triggers a specific immune response. Results will help decide if further testing is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta - Hope Clinic
Decatur, Georgia, 30030, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham & Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Medical Center
New York, New York, 100032, United States
-
New York Blood Center
New York, New York, 10065, United States
-
Penn Prevention CRS [Site ID: 30310]
Philadelphia, Pennsylvania, 19104, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Vanderbilt Institute for Infection, Immunology and Inflammation
Nashville, Tennessee, 37232-2582, United States
Conditions
Explore the condition pages connected to this study.